An innovative dosimetric model for formulating a semi-analytical solution for the activity-volume relationship in prostate implants
An innovative (and yet simple) dosimetric model is proposed that provides a semi-analytical solution to the total activity-volume relationship in ultrasound-guided transperineal prostate implant. This dosimetric model is based on 4 simple assumptions. First, the prostate target volume is approximated as a sphere. Second, the urethra is presumed to transverse through the center of the prostate target volume. Third, peripheral loading is applied as the seed-loading technique. Fourth, as the major innovation of the proposed model, the radial dose function of the Iodine-125 {sup 125}I seed is forced to fit a simple power function of the distance r. Pursuant to the third assumption, the peripherally-loaded seeds also define a spherical volume defined as the loading volume w. Also pursuant to the fourth assumption, the radial dose function is expressed as 1.139*r{sup -0.474} for r = 1.5 to 2.5 cm. Thereafter, a simple analytical power-law equation, A = 1.630* w{sup 0.825}, for the relationship between the total activity A in mCi and the loading volume w in cc is derived for {sup 125}I monotherapy. Isodose plans for loading volumes corresponding to r = 1.5, 1.8, 2.2, and 2.5 cm were performed. The maximal isodose coverage volume {sub max}V100 was calculated for each case and was found to be on the average 65% larger than the loading volume w. Matching prostate target volume V to the loading volume w therefore yields a generous implant (with a margin of approximately 3.3 mm). Conversely, matching the prostate target volume V to the {sub max}V100 yields a tight implant (with 0.0 mm or no margin). Matching the prostate target volume V to a midpoint between the loading volume w and {sub max}V100 yields a moderate implant (with approximately 1- to 2-mm margin). Three individual equations are derived for each type of implants: A = 1.630* V{sup 0.825}, A = 1.288* V{sup 0.825}, or A = 1.078 V{sup 0.825} for generous, tight, or moderate implants, respectively. Patient data at the Chicago Prostate Cancer Center are found to support the above dosimetric model and the 3 semi-analytically derived equations. The above equations are also compared favorably with some of the previously published equations from other authors. These results support the efficacy of the proposed dosimetric model.
- OSTI ID:
- 20655462
- Journal Information:
- Medical Dosimetry, Vol. 28, Issue 4; Other Information: DOI: 10.1016/j.meddos.2003.03.001; PII: S0958394703001043; Copyright (c) 2003 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0958-3947
- Country of Publication:
- United States
- Language:
- English
Similar Records
Establishing High-Quality Prostate Brachytherapy Using a Phantom Simulator Training Program
Monte Carlo investigation of I-125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET